Search Results - "Thayu, M."

Predictors of bone biomarkers in children and adolescents with Crohn disease by Tuchman, S, Thayu, M, Zemel, B.S, Burnham, J.M, Leonard, M.B

Get full text

Improvement in a biomarker of bone formation during infliximab therapy in pediatric Crohn disease: Results of the REACH study by Thayu, M, Leonard, M, Hyams, J, Crandall, W, Kugathasan, S, Otley, A, Olsen, A, Xu, S, Marano, C, Heuschkel, R, Veereman-Wauters, G, Griffiths, A, Baldassano, R, REACH Study Group

Get full text

20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC) by Trigo, J., Cho, B.C., Park, K., Girard, N., Viteri, S., Garrido, P., Krebs, M.G., Thayu, M., Knoblauch, R.E., Xie, J., Bauml, J.M., Schnepp, R.W., Londhe, A., Mahadevia, P., Leighl, N.

Get full text

1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2 by Shu, C.A., Goto, K., Ohe, Y., Besse, B., Park, K., Wang, Y., Griesinger, F., Yang, J.C-H., Felip, E., Sanborn, R.E., Caro, R. Bernabe, Bauml, J.M., Chen, J., Fennema, E., Mahoney, J., Trani, L., Knoblauch, R.E., Thayu, M., Cho, B.C.

Get full text

1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab by Park, K., Sabari, J.K., Haura, E.B., Shu, C.A., Spira, A., Salgia, R., Reckamp, K.L., Sanborn, R.E., Govindan, R., Bauml, J.M., Curtin, J.C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R.E., Cho, B.C.

Get full text

1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study by Leighl, N.B., Shu, C.A., Minchom, A., Felip, E., Cousin, S., Cho, B.C., Park, K., Han, J-Y., Boyer, M., Lee, C.K., Garcia, V. Moreno, Tomasini, P., Viteri, S., Xie, J., Mertz, J., Artis, E., Schnepp, R.W., Knoblauch, R.E., Thayu, M., Perez, J.M. Trigo

Get full text

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC by Cho, B.C., Lee, K.H., Cho, E.K., Kim, D-W., Lee, J-S., Han, J-Y., Kim, S-W., Spira, A., Haura, E.B., Sabari, J.K., Sanborn, R.E., Bauml, J.M., Gomez, J.E., Lorenzini, P., Infante, J.R., Xie, J., Haddish-Berhane, N., Thayu, M., Knoblauch, R.E., Park, K.

Get full text

Skeletal Health of Children and Adolescents With Inflammatory Bowel Disease

Get full text

Evaluation of T-cell receptor gene rearrangements in patients with recurrent patch/plaque (T2) CTCL (mycosis fungoides) by Thayu, M, Tallini, G, Glusac, E J, Kacinski, B M, Wilson, L D

“…Cutaneous T-cell lymphoma is typically a clonal neoplasm of epidermotropic CD4+ T-lymphocytes that includes the entity mycosis fungoides (MF). After…”
Get full text

P-112: The association between drug levels, anti-drug antibodies, and therapeutic response during infliximab therapy in pediatric Crohn’s disease by Stein, R.E., Lee, D.Y., Leonard, M.B., Thayu, M., Herskovitz, R.M., Kerbowski, T., Baldassano, R.N.

Get full text

Hepatosplenic T-Cell Lymphoma in an Adolescent Patient after Immunomodulator and Biologic Therapy for Crohn Disease by Thayu, Meena, Markowitz, Jonathan E, Mamula, Petar, Russo, Pierre A, Muinos, William I, Baldassano, Robert N

Get full text

Improvement in a Biomarker of Bone Formation during Infliximab Therapy in Pediatric Crohn's Disease: Results of the REACH Study by Thayu, M, Leonard, M, Hyams, J, Crandall, W, Kugathasan, S, Otley, A, Olson, A, Liu, G, Marano, C, Heuschkel, R, Veereman‐Wauters, G, Griffiths, A, Baldassano, R

Get full text

Cardiac ischemia during hemolytic uremic syndrome by Thayu, Meena, Chandler, Wayne L, Jelacic, Srdjan, Gordon, Carrie A, Rosenthal, Geoffrey L, Tarr, Phillip I

“…Increased thrombin generation and impaired fibrinolysis during Escherichia coli O157:H7-associated hemolytic uremic syndrome (HUS) plausibly diminish…”
Get full text

Impact of intrapartum antibiotics on the care and evaluation of the neonate by BALTER, SHARON, ZELL, ELIZABETH R, O’BRIEN, KATHERINE L, ROOME, AARON, NOGA, HEATHER, THAYU, MEENA, SCHUCHAT, ANNE

“…BACKGROUND.Management of infants whose mothers receive intrapartum antibiotic prophylaxis (IAP) is controversial. In 1996 consensus guidelines for prevention…”
Get full text

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414) by Pillai, Rathi N., Ramalingam, Suresh S., Thayu, Meena, Lorenzini, Patricia, Alvarez Arias, Diana A., Moy, Christopher, Hutnick, Natalie, Knoblauch, Roland, Feng, Huaibao, Kane, Colleen, Horn, Leora, Reck, Martin, Ponce, Santiago

“…The programmed death-ligand 1 inhibitor atezolizumab improves progression-free survival (PFS) and overall survival (OS) for patients with previously treated…”
Get full text

CDC GROUP IV c-2 BACTEREMIA IN A CHILD WITH RECURRENT ACUTE MONOBLASTIC LEUKEMIA by Thayu, Meena, Baltimore, Robert S, Sleight, Barbara J, Reyes-Mugica, Miguel, Hotez, Peter J

Get full text

Body Composition Abnormalities in Long-Term Survivors of Pediatric Hematopoietic Stem Cell Transplantation by Mostoufi-Moab, Sogol, MD, MSCE, Ginsberg, Jill P., MD, Bunin, Nancy, MD, Zemel, Babette S., PhD, Shults, Justine, PhD, Thayu, Meena, MD, MSCE, Leonard, Mary B., MD, MSCE

“…Objective To quantify lean mass (LM) and fat mass (FM) in survivors of childhood allogeneic hematopoietic stem-cell transplantation (alloHSCT) compared with…”
Get full text

Increases in Sex Hormones during Anti-Tumor Necrosis Factor α Therapy in Adolescents with Crohn's Disease by DeBoer, Mark D., MD, MSc, MCR, Thayu, Meena, MD, Griffin, Lindsay M., MD, Baldassano, Robert N., MD, Denson, Lee A., MD, Zemel, Babette S., MD, Denburg, Michelle R., MD, Agard, Hannah E., BS, Herskovitz, Rita, MS, Long, Jin, PhD, Leonard, Mary B., MD

“…Objective To evaluate children with Crohn's disease for inverse relationships between systemic inflammatory cytokines and sex hormone regulation in the context…”
Get full text

Interpretation of Biomarkers of Bone Metabolism in Children: Impact of Growth Velocity and Body Size in Healthy Children and Chronic Disease by Tuchman, Shamir, MD, MPH, Thayu, Meena, MD, Shults, Justine, PhD, Zemel, Babette S., PhD, Burnham, Jon M., MD, MSCE, Leonard, Mary B., MD, MSCE

“…Objectives To determine the effects of growth, maturation, and whole body bone mineral content (WB-BMC) accrual on biomarkers of bone formation (bone-specific…”
Get full text